Nephrology Times
Advertisement
Novo Nordisk is suing KBP Biosciences over alleged fraudulent claims about the kidney disease drug ocedurenone.
A systematic evaluation compared the incidence of IgAN and changes in its pathology before and during the COVID-19 pandemic.
Researchers studied osteoporosis prevalence and risk factors in Chinese patients with lupus nephritis.
A team analyzed sotagliflozin's effects on hemoglobin in patients with stage 3-4 CKD and type 2 diabetes.
Nephrology Times spoke with Amber Sanchez, MD, about the use of apheresis in nephrology.
Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.
A teen who presented with nephrotic syndrome was diagnosed with both dense deposit disease and IgA nephropathy.
Researchers reported the progression of kidney function throughout the course of IgA nephropathy.
Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks?
The KidneyVault Portable Renal Perfusion System has been used in human kidney transplants for the first time.
Jessica Strawn explains why being aware of patients' past trauma should be of concern to kidney care providers.
A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia.
Eli Lilly ended a phase II trial of volenrelaxin in chronic kidney disease "due to a lack of foreseeable clinical benefit."
Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis.
Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is unclear.
A review and meta-analysis assessed the influence of SGLT2i therapy on clinically relevant hyperuricemic events.
Using NURTuRE-CKD data, researchers studied kidney outcomes and heterogeneity of risk by primary renal diagnosis.
The NKF will invest in the NoMo Kidney Pump, a continuous perfusion system to modernize kidney preservation and storage.
The FDA has granted ODD and RPDD designations to ABO-101 to treat primary hyperoxaluria type 1 (PH1).
Monlunabant failed in a study of its use in DKD, but Novo Nordisk had positive news about other kidney treatments in 2024.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.